Halotestin and Semax Interaction: Monitor | Peptide Database

Join others researching Oxandrolone — share findings, ask questions, and learn from real experiences Oxandrolone is a synthetic oral anabolic-androgenic steroid derived from dihydrotestosterone (DHT), first synthesized in 1962 by Raphael Pappo at Searle Laboratories and introduced to the market in 1964 under the brand name Anavar. It was designed to be a mild anabolic agent with minimal androgenic activity, achieved through a structural modification where an oxygen atom replaces the carbon-2 atom in the A-ring of the DHT backbone. This modification significantly reduces androgenic potency while preserving anabolic effects on skeletal muscle. Oxandrolone is FDA-approved for the promotion of weight regain following involuntary weight loss due to surgery, chronic infection, severe trauma, and prolonged corticosteroid use, and for the relief of bone pain associated with osteoporosis. It has been extensively studied in burn recovery, HIV/AIDS-related wasting, and pediatric growth disorders. Among oral anabolic steroids, oxandrolone is considered one of the mildest with respect to hepatotoxicity and virilizing side effects, which has made it one of the few anabolic steroids used in women and children in clinical settings. Oxandrolone exerts its anabolic effects primarily through binding to the intracellular androgen receptor (AR), promoting nitrogen retention and protein synthesis in skeletal muscle tissue. As a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme, which means it does not cause estrogen-mediated water retention or gynecomastia. The 2-oxo modification in the A-ring reduces its affinity for 5-alpha reductase, limiting conversion to more potent androgens in peripheral tissues and contributing to its relatively low androgenic profile. Oxandrolone increases protein synthesis through direct AR-mediated gene transcription, enhances the expression of genes involved in muscle hypertrophy and repair, and promotes collagen synthesis. It has also been shown to reduce cortisol-binding globulin levels and attenuate the catabolic effects of glucocorticoids, which is particularly relevant in burn patients and those recovering from severe trauma. Additionally, oxandrolone stimulates hepatic production of sex hormone-binding globulin (SHBG) to a lesser degree than other oral steroids, though it does suppress endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal axis.

Join others researching Ezetimibe — share findings, ask questions, and learn from real experiences Ezetimibe is a selective cholesterol absorption inhibitor that blocks the Niemann-Pick C1-Like 1 (NPC1L1) protein in the brush border of the small intestine, preventing dietary and biliary cholesterol from entering the bloodstream. Approved by the FDA in 2002, it occupies a unique niche among lipid-lowering agents by targeting intestinal cholesterol uptake rather than hepatic cholesterol synthesis. In the context of anabolic steroid use, ezetimibe has become a go-to ancillary compound for managing the dyslipidemia that accompanies many AAS cycles, particularly oral steroids like oxandrolone (Anavar) and stanozolol (Winstrol) that are notorious for crashing HDL cholesterol and elevating LDL. While statins remain the first-line treatment for hypercholesterolemia in the general population, ezetimibe is frequently used alone or stacked with a statin by steroid users seeking to mitigate cycle-induced lipid damage without adding yet another hepatotoxic compound to the mix. Ezetimibe selectively inhibits the NPC1L1 transporter protein located on the luminal surface of enterocytes in the jejunum of the small intestine. NPC1L1 is the critical gateway for intestinal cholesterol absorption, responsible for uptaking both dietary cholesterol and the much larger pool of biliary cholesterol that is recirculated through the enterohepatic cycle. By blocking this transporter, ezetimibe reduces cholesterol delivery to the liver, which in turn upregulates hepatic LDL receptor expression to compensate for the reduced cholesterol supply. This upregulation increases LDL clearance from the bloodstream. The mechanism is entirely complementary to statins, which inhibit HMG-CoA reductase to reduce hepatic cholesterol synthesis. When the liver is deprived of cholesterol from both sources simultaneously, the LDL-lowering effect is significantly amplified. Ezetimibe undergoes glucuronidation in the intestinal wall and liver to form its active metabolite, ezetimibe-glucuronide, which is also pharmacologically active and participates in enterohepatic recirculation, contributing to the drug's prolonged duration of action.